Logo
x

Search

Subscribe Now

 US

ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)

ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)

  • November 7, 2024
Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications

Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications

  • October 30, 2024
GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline

GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline

  • October 30, 2024
New Drug Designations - September 2024

New Drug Designations - September 2024

  • October 29, 2024
Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD

Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD

  • October 29, 2024
Modalis Therapeutics’ MDL-101 Gains the US FDA’s Orphan Drug Designation to Treat Congenital Muscular Dystrophy Type 1A (LAMA2-CMD)

Modalis Therapeutics’ MDL-101 Gains the US FDA’s Orphan Drug Designation to Treat Congenital Muscular Dystrophy Type 1A (LAMA2-CMD...

  • October 28, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.